Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:28:19 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Z:PTN - PALATIN TECHNOLOGIES INC - http://www.palatin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PTN - Z0.11.57·2.000.11.82+0.105.8118.91772951.72  1.83  1.685.65  1.4316:59:38Apr 0815 min RT 2¢

Recent Trades - Last 10 of 295
Time ETExPriceChangeVolume
16:59:38Z1.840.1211
16:17:54Z1.810.095
16:04:28Z1.810.0910
15:59:50Z1.820.10363
15:59:24Z1.810.095
15:58:39Z1.8150.095100
15:58:25Z1.820.103
15:58:20Z1.820.105
15:58:14Z1.830.1178
15:57:49Z1.830.11100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 07:30U:PTNNews ReleasePalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
2024-02-28 07:30U:PTNNews ReleasePalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
2024-02-15 07:30U:PTNNews ReleasePalatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
2024-02-09 07:30U:PTNNews ReleasePalatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
2024-02-05 07:30U:PTNNews ReleasePalatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
2024-02-01 16:00U:PTNNews ReleasePalatin Announces Closing of $10 Million Registered Direct Offering
2024-01-30 08:00U:PTNNews ReleasePalatin Announces $10 Million Registered Direct Offering
2024-01-08 10:33U:PTNNews ReleasePalatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
2024-01-03 08:00U:PTNNews ReleaseCosette Pharmaceuticals Acquires Vyleesi ‚ ® (Bremelanotide Injection) from Palatin Technologies Inc.
2023-12-20 07:30U:PTNNews ReleasePalatin Completes Sale of Vyleesi ‚ ® to Cosette Pharmaceuticals for up to $171 Million
2023-12-18 16:15U:PTNNews ReleasePalatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
2023-11-14 07:30U:PTNNews ReleasePalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
2023-11-09 07:30U:PTNNews ReleasePalatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
2023-10-24 16:50U:PTNNews ReleasePalatin Announces Closing of $5 Million Registered Direct Offering
2023-10-23 07:30U:PTNNews ReleasePalatin Announces $5 Million Registered Direct Offering
2023-10-19 07:30U:PTNNews ReleasePalatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi ‚ ® Product Revenue Results
2023-10-18 07:30U:PTNNews ReleasePalatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
2023-10-16 07:30U:PTNNews ReleasePalatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
2023-10-13 16:15U:PTNNews ReleasePalatin Receives Notice of Non-Compliance from NYSE American
2023-09-28 07:30U:PTNNews ReleasePalatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update